Documentation
Associated Media:
Description:
COVID-19 has caused the greatest pandemic in living memory. Alongside providing excellent clinical care in the most challenging of environments, there is also a critical need for clinical research to better understand this disease. This will equip us to better deal with the current pandemic as well future ones.
We need to establish why some people develop severe disease and others never get ill despite infection. We need to know whether there are targets for drug development to treat the disease or to give people who are exposed. We will look at genetic influences and immunology (including prior protective viral exposure), seek neutralising antibodies, understand the cellular responses and assess ethnic and sociological factors – all by collecting a biorepository of over 200,000 samples taken from our own healthcare staff weekly over the next 4 months. These samples will then be divided up and sent to the UKs best academic and pharmaceutical research institutions for collaborative, swift science maximising the yield of the consortium to answer the questions in such urgent need of answers.
Dr Charlotte Manisty, Professor James Moon and their team embarked on a pioneering project with Barts NHS Health Trust, in collaboration with University College London (UCL) and Queen Mary’s University London (QMLU). Their research focused on gathering blood samples and health data from frontline healthcare workers, rather than patients admitted to hospital with COVID-19. This was because healthcare workers have high exposure rates to the disease – it also allows researchers to compare samples from each person before, during and after their exposure to COVID-19, and to investigate the disease in people who develop only mild symptoms or are asymptomatic.
Coverage
Spatial:
United Kingdom,England,London
Typical Age Range:
18-65
Follow Up:
Other
Provenance
Origin
Purposes:
Study
Collection Situations:
Clinic
Temporal
Accrual Periodicity:
Other
Start Date:
19 March 2020
Time Lag:
Variable
Accessibility
Access
Access Rights:
Access Service:
The transfer of samples and/or data will be subject to material and data
transfer agreements between the recipient and each of the institutions
participating in COVID-19 HCW Bioresource. Data sharing will be linked by
COVID-19 HCW Bioresource unique identification number only and restricted to
specific data fields required to undertake each approved pre-specified analysis.
Data will be transferred by the provider to the recipient in an encrypted
electronic format. The recipient will be mandated to have undertaken up to date
information governance training and to use the data in accordance with GDPR
principles. The recipient will ensure that the data are stored in a password
protected encrypted format; are protected by up to date anti-virus and
anti-malware software; are used solely to undertake the pre-specified analysis
and will not be forwarded to a third party. The use of all samples and data will
be limited to the approved application for access and stipulated in the material
and data transfer agreements between participating sites and investigators
requesting access. Return of residual samples will be a condition of the
material transfer agreements. All studies using COVID-19 HCW Bioresource will be
required to submit annual reports to the Executive Committee and all the raw
data obtained from access to COVID-19 HCW Bioresource samples must be deposited
within the COVID-19 HCW Bioresource database.
Delivery Lead Time:
Not applicable
Data Controller:
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
other/xlsx